PhaseII study of S-1/CDDP therapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1

Phase 2

• Conditions: Gastric Cancer

• Registration Number: JPRN-UMIN000004303
• Lead Sponsor: Kyushu Study group of Clinical Cancer

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-09-30
• Study Completion: 2017-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Not provided

Exclusion Criteria

1. Active other malignancies. 2. Prior S-1 plus other anti-cancer drugs combination chemotherapy. 3. Adjuvant chemotherapy other than S-1 mono therapy. 4. Requiring flucytosine, phenytoin, Warfarin Potassium. 5. History of the severe(grade3 or 4) hypersensitivity 6. Co-mobility, such as interstitial lung disease, lung fibrosis, intestinal paralysis, ileus, uncontrolled diabetes, uncontrolled hypertension, heart failure, serious arrhythmia, myocardial infarction, unstable angina, hepatic failure, liver cirrhosis, requiring anticoagulation therapy, requiring steroid drug, and other severe complication. 7. Active infection 8. Infection with hepatitis B or C virus 9. Watery stools or diarrhea 10. Pregnant or lactating woman 11. No birth-control 12. Mental disorder, central nerve disorder. 13. Infection with HIV virus. 14. Not appropriate for the study at the physician's assessment

Study & Design

• Study Type: Interventional
• Study Design: Not specified